The "cure" for cancer: Can the media report the hope without the hype?

Journal of Clinical Oncology

Volumn 20, Issue 18, 2002, Pages 3761-3764

  Daugherty, Christopher K ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; ENDOSTATIN;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL TRIAL; DEATH; DECISION MAKING; EDITORIAL; HUMAN; ONCOLOGY; PHYSICIAN; PRIORITY JOURNAL;

EID: 0037106389     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.18.3761     Document Type: Editorial

References (18)

1. The initial clinical trial of nitrogen mustard
2. From atom to eve
3. Clinical experiences with the use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride (nitrogen mustards) in the therapy of Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders
4. Nitrogen mustard therapy: Studies on the effect of methyl-bis (beta-chloroethyl) amine hydrochloride on neoplastic and allied disorders of the hematopoietic system
5. Hope in the lab
6. Medical researchers and the media: Attitudes toward public dissemination of research
7. Advertising insert. Cancer Clinical Trials: Your first decision counts
8. "Therapeutic misconception" and "recruiting doublespeak" in the informed consent process
9. DTC clinical trial advertising
10. Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial
11. Perceptions of cancer patients and their physicians involved in phase I clinical trials
12. Quantitative analysis of ethical issues in phase I trials: A survey interview of 144 advanced cancer patients
13. Referral and decision making among advanced cancer patients participating in phase I trials at a single institution
14. Phase I study of recombinant human endostatin in patients with advanced solid tumors
15. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily
16. Time article sparks howling headlines, hysteria on Wall Street
17. Patients' opinions, feelings, and attitudes after a campaign to promote Di Bella therapy